Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | giant cell tumor | Research article

The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities

Authors: Zhenhao Chen, Guanglei Zhao, Feiyan Chen, Jun Xia, Li Jiang

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

In this study, the influence of the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) on the prognosis of giant cell tumor (GCT) of the extremities were investigated.

Methods

The clinical parameters of 163 patients who were diagnosed with GCT of the extremities between July 2008 and January 2018 were retrospectively analyzed. Optimal cutoff values of NLR and PLR were determined using receiver operating characteristic (ROC) analysis. According to optimal cutoff values, patients were divided into high NLR and low NLR groups or high PLR and low PLR groups. Kaplan-Meier and log-rank methods were used to compare the recurrence-free survival (RFS) between the high and low NLR groups, and between the high and low PLR groups. Univariate analysis was performed to determine the influence of age, gender, neutrophil count, lymphocyte count, platelet count, white blood cell count, tumor size, surgical approach and Campanacci stage on the prognosis of giant cell tumor of bone. The main predictors of RFS were determined by Cox multivariate regression analysis.

Results

The optimal cutoff value of NLR in giant cell tumor of the extremities was 2.32, which was used to classify patients into high and low NLR groups. The optimal cutoff value of PLR was 116.81, and was used to classify patients into high and low PLR groups. Campanacci stage, tumor maximum diameter, alkaline phosphatase, and C-reactive protein (CRP) were significantly associated with the high NLR and PLR. Cox multivariate regression analysis revealed that the Campanacci stage (HR = 3.28, 95% CI: 1.24~8.69) and NLR (HR = 4.18, 95% CI: 1.83~9.57) were independent prognostic factors for giant cell tumor of the extremities.

Conclusion

As a novel inflammatory index, NLR has some predictive power for the prognosis of patients with giant cell tumor of the extremities.
Literature
1.
go back to reference Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg. 1986;69(69):106–14. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg. 1986;69(69):106–14.
2.
go back to reference Salerno M. Histogenetic characterization of giant cell tumor of bone. Clin Orthop Related Res. 2008;466(9):2081–91.CrossRef Salerno M. Histogenetic characterization of giant cell tumor of bone. Clin Orthop Related Res. 2008;466(9):2081–91.CrossRef
3.
go back to reference Niu X, Zhang Q, Hao L, Ding Y, Li Y, Xu H, Liu W. Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am. 2012;94(5):461–7.CrossRef Niu X, Zhang Q, Hao L, Ding Y, Li Y, Xu H, Liu W. Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am. 2012;94(5):461–7.CrossRef
4.
go back to reference Szendroi M. Giant-cell tumour of bone. J Bone Joint Surg Br. 2004;86(1):5–12.CrossRef Szendroi M. Giant-cell tumour of bone. J Bone Joint Surg Br. 2004;86(1):5–12.CrossRef
5.
go back to reference Lackman RD, Crawford EA, King JJ, Ogilvie CM. Conservative treatment of Campanacci grade III proximal Humerus Giant cell tumors. Clin Orthop Related Res. 2009;467(5):1355–9.CrossRef Lackman RD, Crawford EA, King JJ, Ogilvie CM. Conservative treatment of Campanacci grade III proximal Humerus Giant cell tumors. Clin Orthop Related Res. 2009;467(5):1355–9.CrossRef
6.
go back to reference Prosser GH, Baloch KGTillman RM, Carter SR, Grimer RJ. Does curettage without adjuvant therapy provide low recurrence rates in Giant-cell tumors of bone? Clin Orthop Relat Res. 2005;435(435):211–8.CrossRef Prosser GH, Baloch KGTillman RM, Carter SR, Grimer RJ. Does curettage without adjuvant therapy provide low recurrence rates in Giant-cell tumors of bone? Clin Orthop Relat Res. 2005;435(435):211–8.CrossRef
7.
go back to reference Sanerkin NG. Malignancy, aggressiveness, and recurrence in giant cell tumor of bone. Cancer. 1980;46(7):1641–9.CrossRef Sanerkin NG. Malignancy, aggressiveness, and recurrence in giant cell tumor of bone. Cancer. 1980;46(7):1641–9.CrossRef
8.
go back to reference Malek F, Krueger P, Hatmi ZN, Malayeri AA, Faezipour H, O'Donnell RJ. Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy. Int Orthop. 2006;30(6):495–8.CrossRef Malek F, Krueger P, Hatmi ZN, Malayeri AA, Faezipour H, O'Donnell RJ. Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy. Int Orthop. 2006;30(6):495–8.CrossRef
9.
go back to reference Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Related Res. 2011;469(2):591–9.CrossRef Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Related Res. 2011;469(2):591–9.CrossRef
10.
go back to reference Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri BA, Moreau G, Davis AM. Giant cell tumor of long bone: a Canadian sarcoma group study. Clin Orthop Relat Res. 2002;397(397):248–58.CrossRef Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri BA, Moreau G, Davis AM. Giant cell tumor of long bone: a Canadian sarcoma group study. Clin Orthop Relat Res. 2002;397(397):248–58.CrossRef
11.
go back to reference Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ. Giant cell tumor of bone. J Am Acad Orthop Surg. 2013;21(2):118–26.CrossRef Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ. Giant cell tumor of bone. J Am Acad Orthop Surg. 2013;21(2):118–26.CrossRef
12.
go back to reference Diakos CI, Charles KA, Mcmillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503.CrossRef Diakos CI, Charles KA, Mcmillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503.CrossRef
13.
go back to reference Xiong Y, Zhao N, Zheng Y, Wang J, Wei F, Ren X. Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet. Tumour Biology the J Int Soc Oncodevelopmental Biol Med. 2017;39(6):1010428317701639.CrossRef Xiong Y, Zhao N, Zheng Y, Wang J, Wei F, Ren X. Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet. Tumour Biology the J Int Soc Oncodevelopmental Biol Med. 2017;39(6):1010428317701639.CrossRef
14.
go back to reference Gu X, Sun S, Gao XS, Wei X, Qin S, Xin Q, Ma M, Li X, Dong Z, Wen W. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. Sci Rep. 2016;6:23893.CrossRef Gu X, Sun S, Gao XS, Wei X, Qin S, Xin Q, Ma M, Li X, Dong Z, Wen W. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. Sci Rep. 2016;6:23893.CrossRef
15.
go back to reference Tan D, Fu Y, Su Q, Wang H. Prognostic role of platelet–lymphocyte ratio in colorectal cancer:a systematic review and meta-analysis. Medicine. 2016;95(24):e3837.CrossRef Tan D, Fu Y, Su Q, Wang H. Prognostic role of platelet–lymphocyte ratio in colorectal cancer:a systematic review and meta-analysis. Medicine. 2016;95(24):e3837.CrossRef
16.
go back to reference Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012;22(1):33–40.CrossRef Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012;22(1):33–40.CrossRef
17.
go back to reference Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.CrossRef Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.CrossRef
18.
go back to reference Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberlmoser R, Samonigg H, Stojakovic T, Gerger A. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110(2):435.CrossRef Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberlmoser R, Samonigg H, Stojakovic T, Gerger A. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110(2):435.CrossRef
19.
go back to reference Jenne CN, Kubes P. Platelets in inflammation and infection. Platelets. 2015;26(4):1–7.CrossRef Jenne CN, Kubes P. Platelets in inflammation and infection. Platelets. 2015;26(4):1–7.CrossRef
20.
go back to reference Ghasemzadeh M, Hosseini E. Platelet-leukocyte crosstalk: linking proinflammatory responses to procoagulant state. Thromb Res. 2013;131(3):191–7.CrossRef Ghasemzadeh M, Hosseini E. Platelet-leukocyte crosstalk: linking proinflammatory responses to procoagulant state. Thromb Res. 2013;131(3):191–7.CrossRef
21.
go back to reference Li J, Xu H, Sun Z, Hou Q, Kwok LY, Laga W, Wang Y, Ma H, Yu Z, Menghe B. Effect of dietary interventions on the intestinal microbiota of Mongolian hosts. Sci Bulletin. 2016;61(20):1605.CrossRef Li J, Xu H, Sun Z, Hou Q, Kwok LY, Laga W, Wang Y, Ma H, Yu Z, Menghe B. Effect of dietary interventions on the intestinal microbiota of Mongolian hosts. Sci Bulletin. 2016;61(20):1605.CrossRef
22.
go back to reference De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clinical Cancer research an official journal of the American association for. Cancer Res. 2004;10(15):4895. De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clinical Cancer research an official journal of the American association for. Cancer Res. 2004;10(15):4895.
23.
go back to reference Miyamoto R, Oda T, Hashimoto S, Kurokawa T, Kohno K, Akashi Y, Ohara Y, Yamada K, Enomoto T, Ohkohchi N. Platelet × CRP multiplier value as an Indicator of poor prognosis in patients with Resectable pancreatic Cancer. Pancreas. 2017;46(1):35.CrossRef Miyamoto R, Oda T, Hashimoto S, Kurokawa T, Kohno K, Akashi Y, Ohara Y, Yamada K, Enomoto T, Ohkohchi N. Platelet × CRP multiplier value as an Indicator of poor prognosis in patients with Resectable pancreatic Cancer. Pancreas. 2017;46(1):35.CrossRef
24.
go back to reference Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48.CrossRef Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48.CrossRef
25.
go back to reference Armistead PM, Wieder E, Akande O, Alatrash G, Quintanilla K, Liang S, Molldrem J. Cyclic neutropenia associated with T cell immunity to granulocyte proteases and a double de novo mutation in GFI1, a transcriptional regulator of ELANE. Br J Haematol. 2010;150(6):716–9.CrossRef Armistead PM, Wieder E, Akande O, Alatrash G, Quintanilla K, Liang S, Molldrem J. Cyclic neutropenia associated with T cell immunity to granulocyte proteases and a double de novo mutation in GFI1, a transcriptional regulator of ELANE. Br J Haematol. 2010;150(6):716–9.CrossRef
26.
go back to reference Hock BD, Taylor KG, Cross NB, Kettle AJ, Hampton MB, Mckenzie JL. Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability. Immunology. 2012;137(3):249–58.CrossRef Hock BD, Taylor KG, Cross NB, Kettle AJ, Hampton MB, Mckenzie JL. Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability. Immunology. 2012;137(3):249–58.CrossRef
27.
go back to reference Kim H, Ro SM, Yang JH, Jeong JW, Lee JE, Roh SY, Kim IH. The neutrophil-to-lymphocyte ratio prechemotherapy and postchemotherapy as a prognostic marker in metastatic gastric cancer. The Korean J Internal Med. 2018;33(5):990–9.CrossRef Kim H, Ro SM, Yang JH, Jeong JW, Lee JE, Roh SY, Kim IH. The neutrophil-to-lymphocyte ratio prechemotherapy and postchemotherapy as a prognostic marker in metastatic gastric cancer. The Korean J Internal Med. 2018;33(5):990–9.CrossRef
28.
go back to reference Li Y, Wang C, Xu M, Kong C, Qu A, Zhang M, Zheng Z, Zhang G. Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer. J Can Res Clin Oncol. 2017;143(5):861–71.CrossRef Li Y, Wang C, Xu M, Kong C, Qu A, Zhang M, Zheng Z, Zhang G. Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer. J Can Res Clin Oncol. 2017;143(5):861–71.CrossRef
29.
go back to reference Yang HJ, Guo Z, Yang YT, Jiang JH, Qi YP, Li JJ, Li LQ, Xiang BD. Blood neutrophil-lymphocyte ratio predicts survival after hepatectomy for hepatocellular carcinoma: a propensity score-based analysis. World J Gastroenterol. 2016;22(21):5088.CrossRef Yang HJ, Guo Z, Yang YT, Jiang JH, Qi YP, Li JJ, Li LQ, Xiang BD. Blood neutrophil-lymphocyte ratio predicts survival after hepatectomy for hepatocellular carcinoma: a propensity score-based analysis. World J Gastroenterol. 2016;22(21):5088.CrossRef
30.
go back to reference Zhao Y, Si G, Zhu F, Hui J, Cai S, Huang C, Cheng S, Fathy AH, Xiang Y, Li J. Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget. 2017;8(14):22854–62.PubMedPubMedCentral Zhao Y, Si G, Zhu F, Hui J, Cai S, Huang C, Cheng S, Fathy AH, Xiang Y, Li J. Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget. 2017;8(14):22854–62.PubMedPubMedCentral
31.
go back to reference Yildirim MA, Seckin KD, Togrul C, Baser E, Karsli MF, Gungor T, Gulerman HC. Roles of neutrophil/lymphocyte and platelet/lymphocyte ratios in the early diagnosis of malignant ovarian masses. Asian Pacific J Can Prevent Apjcp. 2014;15(16):6881.CrossRef Yildirim MA, Seckin KD, Togrul C, Baser E, Karsli MF, Gungor T, Gulerman HC. Roles of neutrophil/lymphocyte and platelet/lymphocyte ratios in the early diagnosis of malignant ovarian masses. Asian Pacific J Can Prevent Apjcp. 2014;15(16):6881.CrossRef
32.
go back to reference Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;286:241–6. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;286:241–6.
33.
go back to reference Rücker G, Schumacher M. Summary ROC curve based on a weighted Youden index for selecting an optimal cutpoint in meta-analysis of diagnostic accuracy. Stat Med. 2011;29(30):3069–78.CrossRef Rücker G, Schumacher M. Summary ROC curve based on a weighted Youden index for selecting an optimal cutpoint in meta-analysis of diagnostic accuracy. Stat Med. 2011;29(30):3069–78.CrossRef
34.
go back to reference Lin WF, Zhong MF, Zhang YR, Wang H, Zhao HT, Cheng BB, Ling CQ. Prognostic role of platelet-to-lymphocyte ratio in hepatocellular carcinoma with different BCLC stages: a systematic review and meta-analysis. Gastroenterol Res Pract. 2018;2018:5670949.CrossRef Lin WF, Zhong MF, Zhang YR, Wang H, Zhao HT, Cheng BB, Ling CQ. Prognostic role of platelet-to-lymphocyte ratio in hepatocellular carcinoma with different BCLC stages: a systematic review and meta-analysis. Gastroenterol Res Pract. 2018;2018:5670949.CrossRef
35.
go back to reference He W, Yin C, Guo G, Jiang C. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte;ratio as an adverse prognostic and predictive factor in metastatic;colorectal cancer. Med Oncol. 2013;30(1):439.CrossRef He W, Yin C, Guo G, Jiang C. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte;ratio as an adverse prognostic and predictive factor in metastatic;colorectal cancer. Med Oncol. 2013;30(1):439.CrossRef
36.
go back to reference Salisbury JR. Histological typing of bone Tumours. J Clin Pathol. 1993;47(6):571.CrossRef Salisbury JR. Histological typing of bone Tumours. J Clin Pathol. 1993;47(6):571.CrossRef
37.
go back to reference Teixeira LE, Vilela JC, Miranda RH, Gomes AH, Costa FA, de Faria VC. Giant cell tumors of bone: nonsurgical factors associated with local recurrence. Acta Orthop Traumatol Turc. 2014;48(2):136.CrossRef Teixeira LE, Vilela JC, Miranda RH, Gomes AH, Costa FA, de Faria VC. Giant cell tumors of bone: nonsurgical factors associated with local recurrence. Acta Orthop Traumatol Turc. 2014;48(2):136.CrossRef
38.
go back to reference Errani C, Ruggieri P, Asenzio MAN, Toscano A, Colangeli S, Rimondi E, Rossi G, Longhi A, Mercuri M. Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev. 2010;36(1):1–7.CrossRef Errani C, Ruggieri P, Asenzio MAN, Toscano A, Colangeli S, Rimondi E, Rossi G, Longhi A, Mercuri M. Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev. 2010;36(1):1–7.CrossRef
39.
go back to reference Wang C-S, Lou J-H, Liao J-S, Ding X-Y, Du L-J. Recurrence in giant cell tumour of bone: imaging features and risk;factors. La Radiologia Medica. 2013;118(3):456–64.CrossRef Wang C-S, Lou J-H, Liao J-S, Ding X-Y, Du L-J. Recurrence in giant cell tumour of bone: imaging features and risk;factors. La Radiologia Medica. 2013;118(3):456–64.CrossRef
40.
go back to reference Li D, Zhang J, Yi L, Xia J, Yang Y, Ren M, Liao Y, Yu S, Li X, Yan S. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone. World J Surg Oncol. 2016;14(1):114.CrossRef Li D, Zhang J, Yi L, Xia J, Yang Y, Ren M, Liao Y, Yu S, Li X, Yan S. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone. World J Surg Oncol. 2016;14(1):114.CrossRef
41.
go back to reference Deheshi BM, Jaffer SN, Griffin AM, Ferguson PC, Bell RS, Wunder JS. Joint salvage for pathologic fracture of giant cell tumor of the lower extremity. Clin Orthop Related Res. 2007;459(459):96–104.CrossRef Deheshi BM, Jaffer SN, Griffin AM, Ferguson PC, Bell RS, Wunder JS. Joint salvage for pathologic fracture of giant cell tumor of the lower extremity. Clin Orthop Related Res. 2007;459(459):96–104.CrossRef
42.
go back to reference Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HC, Jorgensen PH, Bergh P. Follerã¥S G. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian sarcoma group study of 294 patients followed for a median time of 5 years. Acta Orthop. 2008;79(1):86–93.CrossRef Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HC, Jorgensen PH, Bergh P. Follerã¥S G. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian sarcoma group study of 294 patients followed for a median time of 5 years. Acta Orthop. 2008;79(1):86–93.CrossRef
43.
go back to reference Sakayama K, Sugawara Y, Kidani T, Miyawaki J, Fujibuchi T, Kamei S, Aizawa J, Yamamoto H. Diagnostic and therapeutic problems of giant cell tumor in the proximal femur. Arch Orthop Trauma Surg. 2007;127(10):867–72.CrossRef Sakayama K, Sugawara Y, Kidani T, Miyawaki J, Fujibuchi T, Kamei S, Aizawa J, Yamamoto H. Diagnostic and therapeutic problems of giant cell tumor in the proximal femur. Arch Orthop Trauma Surg. 2007;127(10):867–72.CrossRef
44.
go back to reference Rock MG, Pritchard DJ, Unni KK. Metastases from histologically benign giant-cell tumor of bone. J Bone Joint Surg (Am Vol). 1984;66(2):269–74.CrossRef Rock MG, Pritchard DJ, Unni KK. Metastases from histologically benign giant-cell tumor of bone. J Bone Joint Surg (Am Vol). 1984;66(2):269–74.CrossRef
45.
go back to reference Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol. 2010;28(26):4045–51.CrossRef Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol. 2010;28(26):4045–51.CrossRef
Metadata
Title
The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities
Authors
Zhenhao Chen
Guanglei Zhao
Feiyan Chen
Jun Xia
Li Jiang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5511-x

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine